These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26429174)

  • 1. Histological and immunohistochemical aspects of papillary thyroid cancer.
    Radu TG; Mogoantă L; Busuioc CJ; Stănescu C; Grosu F
    Rom J Morphol Embryol; 2015; 56(2 Suppl):789-95. PubMed ID: 26429174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma.
    Tan A; Etit D; Bayol U; Altinel D; Tan S
    Ann Diagn Pathol; 2011 Apr; 15(2):108-16. PubMed ID: 21315633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of nuclear 8-hydroxyguanosine expression in Autoimmune Thyroid Diseases and Papillary Thyroid Carcinoma and its relationship with p53, Bcl-2 and Ki-67 cancer related proteins.
    Mseddi M; Ben Mansour R; Gouiia N; Mnif F; Bousselaa R; Abid M; Boudaouara T; Attia H; Lassoued S
    Adv Med Sci; 2017 Mar; 62(1):45-51. PubMed ID: 28187375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients.
    Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A
    Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules.
    Ozolins A; Narbuts Z; Strumfa I; Volanska G; Stepanovs K; Gardovskis J
    Medicina (Kaunas); 2012; 48(10):507-14. PubMed ID: 23324246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
    Abouhashem NS; Talaat SM
    Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
    Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
    Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid tumors of uncertain malignant potential: morphologic and imunohistochemical analysis of 29 cases.
    Nechifor-Boila A; Borda A; Sassolas G; Hafdi-Nejjari Z; Cătană R; Borson-Chazot F; Berger N; Decaussin-Petrucci M
    Pathol Res Pract; 2015 Apr; 211(4):320-5. PubMed ID: 25595997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of CD56 immunohistochemistry in thyroid lesions.
    Pyo JS; Kim DH; Yang J
    Int J Biol Markers; 2018 May; 33(2):161-167. PubMed ID: 29799356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.
    Saltman B; Singh B; Hedvat CV; Wreesmann VB; Ghossein R
    Surgery; 2006 Dec; 140(6):899-905; discussion 905-6. PubMed ID: 17188136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The expression and clinical significance of EphA2 and E-cadherin in papillary thyroid carcinoma].
    Liu Y; Miao Y; Li X
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jun; 29(11):1020-3. PubMed ID: 26536708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of immunohistochemical panel in various thyroid pathologies.
    Ozolins A; Narbuts Z; Strumfa I; Volanska G; Gardovskis J
    Langenbecks Arch Surg; 2010 Sep; 395(7):885-91. PubMed ID: 20640858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of P53, E-cadherin and BRAF as predictors of regional nodal recurrence for papillary thyroid cancer.
    Ali KM; Awny S; Ibrahim DA; Metwally IH; Hamdy O; Refky B; Abdallah A; Abdelwahab K
    Ann Diagn Pathol; 2019 Jun; 40():59-65. PubMed ID: 31031216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-expression and clinical utility of Snail and N-cadherin in papillary thyroid carcinoma.
    Yang X; Shi R; Zhang J
    Tumour Biol; 2016 Jan; 37(1):413-7. PubMed ID: 26219900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RASSF10 is Epigenetically Inactivated and Suppresses Cell Proliferation and Induces Cell Apoptosis by Activating the p53 Signalling Pathway in Papillary Thyroid Carcinoma Cancer.
    Fan C; Wang W; Jin J; Yu Z; Xin X
    Cell Physiol Biochem; 2017; 41(3):1229-1239. PubMed ID: 28268222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression.
    Preto A; Reis-Filho JS; Ricardo S; Soares P
    Pathol Res Pract; 2002; 198(7):449-54. PubMed ID: 12234063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma.
    Wiseman SM; Griffith OL; Deen S; Rajput A; Masoudi H; Gilks B; Goldstein L; Gown A; Jones SJ
    Arch Surg; 2007 Aug; 142(8):717-27; discussion 727-9. PubMed ID: 17709725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel BRAF and KRAS Mutations in Papillary Thyroid Carcinoma Arising in Struma Ovarii.
    Tan A; Stewart CJ; Garrett KL; Rye M; Cohen PA
    Endocr Pathol; 2015 Dec; 26(4):296-301. PubMed ID: 26362194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the diagnostic value of emerin and CD56 in papillary thyroid carcinoma - an immunohistochemical study.
    Abdou AG; Abdelwahed M; Said A; Taie DM; Fahmy S
    J Immunoassay Immunochem; 2018; 39(5):521-537. PubMed ID: 30188764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
    Tong J; Wang Y; Da JP
    Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.